<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927978</url>
  </required_header>
  <id_info>
    <org_study_id>201207067MIC</org_study_id>
    <nct_id>NCT01927978</nct_id>
  </id_info>
  <brief_title>Using &quot;PET Response Criteria in Solid Tumors (PERCIST)&quot; in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer</brief_title>
  <official_title>Using &quot;PET Response Criteria in Solid Tumors (PERCIST)&quot; in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to evaluate the effectiveness of 18F-FDG PET in the initial staging,
      therapy planning, and therapeutic response monitoring for esophageal cancer patients.

      Purpose:

        1. The incremental staging information by using 18F-FDG PET

        2. The impact of the PET results on the patients' subsequent therapy planning

        3. To compare treatment response using RECIST criteria and FDG PET results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Esophageal cancer is one of the leading malignancies in Taiwan. Accuracy tumor
      staging can direct to appropriate therapy planning and provide prognostic implications.
      Positron emission tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose (FDG) has been shown
      to have better N staging and prognostic stratification abilities than conventional imaging
      modalities, such as endoscopic ultrasonography (EUS) and CT.

      Purpose: This study is aimed to evaluate the effectiveness of 18F-FDG PET in the initial
      staging, therapy planning, and therapeutic response monitoring for esophageal cancer
      patients.

      Method: Patients with pathological proven esophageal cancer, age 20-90 year-old, will be
      included in this study. Each patient will receive a baseline PET study. For those patients
      who received pre-operative CCRT, another PET will be performed 1-4 weeks after completion of
      CCRT.

      Primary outcome: 1. The incremental staging information by using 18F-FDG PET 2. The impact of
      the PET results on the patients' subsequent therapy planning 3. To compare treatment response
      using RECIST criteria and FDG PET results.

      Secondary outcome: To correlate the PET response rate and the patients' disease free survival
      and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The effectiveness of 18F-FDG PET in the initial staging, therapy planning, and therapeutic response monitoring for esophageal cancer patients.</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>esophageal cancer, 18F-FDG PET</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Histological proved esophageal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ageï¼š20-90 years old

          2. Histological proved esophageal cancer

          3. ECOG performance status 0-2

          4. written informed consent signed

        Exclusion Criteria:

          1. prior chemotherapy or treatment for other systemic anti-cancer agent(s)

          2. pregnant or intend to be pregnant

          3. other malignancies known

          4. other concurrent cancer treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yen Ruoh Fang, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yen Ruoh Fang, M.D.,Ph.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65581</phone_ext>
    <email>rfyen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen Ruoh Fang, M.D., Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65581</phone_ext>
      <email>rfyen@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Yen Ruoh Fang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003 Dec 4;349(23):2241-52. Review.</citation>
    <PMID>14657432</PMID>
  </reference>
  <reference>
    <citation>Ng T, Vezeridis MP. Advances in the surgical treatment of esophageal cancer. J Surg Oncol. 2010 Jun 15;101(8):725-9. doi: 10.1002/jso.21566. Review.</citation>
    <PMID>20512949</PMID>
  </reference>
  <reference>
    <citation>Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, Wong D, Ramshaw JE, Scott AM. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61. doi: 10.1007/s00259-008-0959-y. Epub 2008 Oct 18.</citation>
    <PMID>18931839</PMID>
  </reference>
  <reference>
    <citation>Yen TJ, Chung CS, Wu YW, Yen RF, Cheng MF, Lee JM, Hsu CH, Chang YL, Wang HP. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma. Dis Esophagus. 2012 Jan;25(1):40-7. doi: 10.1111/j.1442-2050.2011.01204.x. Epub 2011 May 19.</citation>
    <PMID>21595776</PMID>
  </reference>
  <reference>
    <citation>Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012 Jun;53(6):864-71. doi: 10.2967/jnumed.111.101568. Epub 2012 May 11.</citation>
    <PMID>22582047</PMID>
  </reference>
  <reference>
    <citation>Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, Isohashi K, Kato H, Shimosegawa E, Yamasaki M, Mori M, Doki Y, Hatazawa J. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 2012 Jun;53(6):872-80. doi: 10.2967/jnumed.111.098699. Epub 2012 May 11.</citation>
    <PMID>22582049</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <last_update_submitted>April 13, 2014</last_update_submitted>
  <last_update_submitted_qc>April 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>18F-FDG PET</keyword>
  <keyword>staging</keyword>
  <keyword>therapy planning</keyword>
  <keyword>therapy response monitoring</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

